Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/32082
Başlık: Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Hematoloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı/Çocuk Sağlığı ve Hastalıkları Anabilim Dalı.
Özkocaman, Vildan
Demirkaya, Metin
AAH-1854-2021
6603145040
24331130000
Anahtar kelimeler: Oncology
Hodgkin lymphoma
Resistant/relapsed disease
Programmed death 1 (PD-1) blocker
Nivolumab
Brentuxımab vedotın
PD-1 blockade
Yayın Tarihi: Eki-2017
Yayıncı: Elsevier
Atıf: Beköz, H. vd. (2017). ''Nivolumab for relapsed or refractory Hodgkin lymphoma: Real-life experience''. Annals of Oncology, 28(10), 2496-2502.
Özet: Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile. Patients and methods: We present a retrospective analysis of 82 patients (median age: 30 years; range: 18-75) with relapsed/refractory HL treated with nivolumab in a named patient program from 24 centers throughout Turkey. The median follow-up was 7 months, and the patients had a median of 5 (2-11) previous lines of therapy. Fifty-seven (70%) and 63 (77%) had been treated by stem-cell transplantation and brentuximab vedotin, respectively. Results: Among 75 patients evaluated after 12 weeks of nivolumab treatment, the objective response rate was 64%, with 16 complete responses (CR; 22%); after 16 weeks, it was 60%, with 16 (26%) patients achieving CR. Twenty patients underwent subsequent transplantation. Among 11 patients receiving allogeneic stem-cell transplantation, 5 had CR at the time of transplantation and are currently alive with ongoing response. At the time of analysis, 41 patients remained on nivolumab treatment. Among the patients who discontinued nivolumab, the main reason was disease progression (n = 19). The safety profile was acceptable, with only four patients requiring cessation of nivolumab due to serious adverse events (autoimmune encephalitis, pulmonary adverse event, and two cases of graft-versus-host disease aggravation). The 6-month overall and progression-free survival rates were 91.2% (95% confidence interval: 0.83-0.96) and 77.3% (0.66-0.85), respectively. Ten patients died during the follow-up; one of these was judged to be treatment-related. Conclusions: Nivolumab represents a novel option for patients with cHL refractory to brentuximab vedotin, and may serve as a bridge to transplantation; however, it may be associated with increased toxicity.
Açıklama: "Çalışmada 32 yazar bulunmaktadır. Bu yazarlardan sadece Bursa Uludağ Üniversitesi mensuplarının girişleri yapılmıştır”
URI: https://doi.org/10.1093/annonc/mdx341
https://www.sciencedirect.com/science/article/pii/S0923753419349452
http://hdl.handle.net/11452/32082
ISSN: 0923-7534
1569-8041
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Dosya Açıklama BoyutBiçim 
Demirkaya_vd_2017.pdf250.86 kBAdobe PDFKüçük resim
Göster/Aç


Bu öğe kapsamında lisanslı Creative Commons License Creative Commons